A molecule found in passion fruit shows promising potential in slowing the progression of Alzheimer’s disease, according to research conducted at the University of Oslo. The discovery, building on four years of investigation, centers around alpha-amyrin, a compound that appears to protect key brain processes and could pave the way for new treatments for this devastating neurodegenerative condition. Whereas still early in development, the findings offer a hopeful avenue for addressing a disease that currently affects millions worldwide.
Alzheimer’s disease, the most common cause of dementia, is characterized by a gradual decline in memory, language, and cognitive function. The underlying cause is the buildup of damaging proteins in the brain, disrupting nerve cell function and ultimately leading to cell death. Researchers have long sought ways to prevent or slow this process, and the identification of alpha-amyrin represents a significant step forward. The study, recently published in the journal Advanced Science, details how this naturally occurring molecule interacts with critical cellular mechanisms to offer protection.
Alpha-Amyrin: A “Brain Guardian” Protecting Cellular Energy
The research team, led by Associate Professor Evandro Fei Fang‑Stavem at the University of Oslo and Akershus University Hospital, discovered that alpha-amyrin acts as a protective agent for mitochondria, the “energy factories” within brain cells. As we age, these mitochondria become less efficient at producing energy, and their function is further impaired by the accumulation of waste products associated with Alzheimer’s. “Alpha‑amyrin acts like a kind of ‘brain guardian’, making sure that this rubbish does not build up,” explained Dr. Shu‑qin Cao, postdoctoral fellow and first author of the study, from the University of Oslo.
In laboratory experiments, researchers observed that supplementing mice with Alzheimer’s disease with alpha-amyrin led to a reduction in waste product accumulation and improved performance in memory tests. This suggests that the molecule supports the brain’s natural clearance mechanisms and helps maintain a healthy cellular environment. The positive effects were linked to alpha-amyrin’s ability to modulate a specific cellular pathway – the DLK-SARM1-ULK1 cascade – promoting the activation of ULK1, a protein crucial for mitochondrial quality control and the removal of damaged mitochondria.
How Alpha-Amyrin Reaches the Brain and its Potential for Treatment
A key finding of the study was the demonstration that alpha-amyrin can effectively cross the blood-brain barrier, a protective layer that often hinders the delivery of drugs to the brain. Researchers tested this by observing the molecule’s presence in the brains of healthy mice after supplementation. This ability to reach the brain is critical for any potential therapeutic application. The team found that alpha-amyrin remains in the bloodstream for a sufficient duration to function as an active ingredient in a future medicine.
Interestingly, passion fruit isn’t the only source of alpha-amyrin. The molecule is also found in other colorful fruits and vegetables, including tomatoes and cranberries, according to the research team. “We know from previous research that eating colourful fruit and vegetables is good for the brain,” Dr. Cao noted. “Now we see that these benefits are likely to come from natural ingredients found in this kind of fruit and vegetables, especially in passion fruit. These ingredients protect the mitochondria and help preserve memory.” While dietary intake of these fruits and vegetables is beneficial, the concentrations of alpha-amyrin needed for therapeutic effect may require supplementation, a point researchers are actively investigating.
From Lab to Clinic: Next Steps in Alzheimer’s Research
The University of Oslo has already taken steps toward translating this discovery into potential treatments. Through its Technology Transfer Office (TTO) Inven2 AS, the university has licensed the commercial development of alpha‑amyrin to HK LONGEVITY SCIENCE LABORATORY, a Hong Kong-based company. This licensing agreement signifies a commitment to further research and development, with the ultimate goal of bringing a new therapy to market.
The researchers are now focused on conducting clinical trials to assess the bioavailability, safety, and efficacy of alpha-amyrin in humans with dementia. “We would like bring our investigations of alpha-amyrin further, such as to perform clinical trials…when funding and resources are available,” Dr. Cao explained. Alongside these trials, the team continues to investigate the epidemiological link between the consumption of colorful fruits and vegetables and the risk of dementia, analyzing ten years of population data. Their preliminary findings suggest a correlation between higher consumption of these foods and a reduced risk of developing the disease.
This research represents an international collaboration, involving scientists from the University of Oslo, University of Fribourg (Switzerland), Chulalongkorn University (Thailand), Spanish National Research Council, Huashan Hospital (China), The University of Oxford (UK), and University of Crete (Greece). This collaborative effort underscores the global importance of finding effective treatments for Alzheimer’s disease.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The future of Alzheimer’s treatment remains uncertain, but the discovery of alpha-amyrin offers a promising new direction. Researchers anticipate further updates on clinical trial progress and the potential for this natural compound to become a valuable tool in the fight against this debilitating disease. Share your thoughts on this research and its potential impact in the comments below.
